Skip to main navigation Skip to search Skip to main content

The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer

*Corresponding author
  • University of Perugia
  • Radiation Oncology Centre - S. Maria Misericordia Hospital
  • University of Trieste
  • IRCCS Centro di Riferimento Oncologico - Aviano PN
  • IRCCS Istituto Oncologico Veneto - Padova
  • Gabriele d'Annunzio University
  • Ospedale Vito Fazzi
  • Azienda Ospedaliera S. Maria di Terni
  • Alma Mater Studiorum University of Bologna
  • University of Rome La Sapienza
  • University of Padua

Research output: Contribution to journalArticle

Abstract

N/A
Original languageEnglish
Pages (from-to)110-118
Number of pages9
JournalRadiotherapy and Oncology
Volume134
Issue numberN/A
DOIs
Publication statusPublished - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Keywords

  • Boost
  • Chemoradiation
  • Oxaliplatin
  • Pathologic complete response
  • Preoperative radiochemotherapy
  • Rectal cancer

Fingerprint

Dive into the research topics of 'The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer'. Together they form a unique fingerprint.

Cite this